A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- International journal of cancer
- Publicado em
- 5 fev 2024
- Citações
- 12
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
Valerie Lee, Rose Parkinson, Marianna Zahurak, Leslie Cope, Andrea Cercek, Henk M W Verheul, Elske Gootjes, Heinz-Josef Lenz, Syma Iqbal, Peter Jones et al.
Descritores MeSH
- Rectal Neoplasms
- Thymine
- Trifluridine
- Colorectal Neoplasms
- Colonic Neoplasms
- Anemia
- Azacitidine
- Neutropenia
- Phenylurea Compounds
- Pyridines
Veja também
Estudos relacionados
- Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis
- A systematic review of cost-effectiveness studies of later-line treatments for refractory metastatic colorectal cancer
- Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis
- Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial